Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

UFS scientists involved in groundbreaking research to protect rhino horns
2010-07-27

Pictured from the left are: Prof. Paul Grobler (UFS), Prof. Antoinette Kotze (NZG) and Ms. Karen Ehlers (UFS).
Photo: Supplied

Scientists at the University of the Free State (UFS) are involved in a research study that will help to trace the source of any southern white rhino product to a specific geographic location.

This is an initiative of the National Zoological Gardens of South Africa (NZG).

Prof. Paul Grobler, who is heading the project in the Department of Genetics at the UFS, said that the research might even allow the identification of the individual animal from which a product was derived. This would allow law enforcement agencies not only to determine with certainty whether rhino horn, traded illegally on the international black market, had its origin in South Africa, but also from which region of South Africa the product came.

This additional knowledge is expected to have a major impact on the illicit trade in rhino horn and provide a potent legal club to get at rhino horn smugglers and traders.

The full research team consists of Prof. Grobler; Christiaan Labuschagne, a Ph.D. student at the UFS; Prof. Antoinette Kotze from the NZG, who is also an affiliated professor at the UFS; and Dr Desire Dalton, also from the NZG.

The team’s research involves the identification of small differences in the genetic code among white rhino populations in different regions of South Africa. The genetic code of every species is unique, and is composed of a sequence of the four nucleotide bases G, A, T and C that are inherited from one generation to the next. When one nucleotide base is changed or mutated in an individual, this mutated base is also inherited by the individual's progeny.

If, after many generations, this changed base is present in at least 1% of the individuals of a group, it is described as a single nucleotide polymorphism (SNP), pronounced "snip". Breeding populations that are geographically and reproductively isolated often contain different patterns of such SNPs, which act as a unique genetic signature for each population.

The team is assembling a detailed list of all SNPs found in white rhinos from different regions in South Africa. The work is done in collaboration with the Pretoria-based company, Inqaba Biotech, who is performing the nucleotide sequencing that is required for the identification of the SNPs.

Financial support for the project is provided by the Advanced Biomolecular Research cluster at the UFS.

The southern white rhino was once thought to be extinct, but in a conservation success story the species was boosted from an initial population of about 100 individuals located in KwaZulu-Natal at the end of the 19th century, to the present population of about 15 000 individuals. The southern white rhino is still, however, listed as “near threatened” by the World Wildlife Fund (WWF).

Media Release:
Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za 
27 July 2010



 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept